Hiromasa Ikegami — Endo Lab

article 1991

Effects of nocturnal hyperprolactinemia on ovarian luteal function and galactorrhea

·doi:10.1016/0028-2243(91)90056-q

To determine the effects of nocturnal hyperprolactinemia on luteal function and galactorrhea we studied six diurnal normoprolactinemic women with regular menstrual cycles. The diurnal serum levels of prolactin (PRL), luteinizing hormone (LH…

article 1988

Preliminary report on the use of danazol in the treatment of endometrial adenomatous hyperplasia

·doi:10.1002/1097-0142(19881215)62:12<2618::aid-cncr2820621228>3.0.co;2-i

Since the authors recently reported that danazol inhibits the growth of human endometrial cancer cells in vitro, a clinical trial was initiated to examine whether danazol can regress adenomatous hyperplasia, a precursor of endometrial adeno…

article 1987

Growth inhibition by danazol in a human endometrial cancer cell line with estrogen-independent progesterone receptors

·doi:10.1016/0022-4731(87)90517-6

Since we recently found that danazol, an isoxazol derivative of ethinyltestosterone, has a growth-inhibitory effect on human endometrial cancer cells in primary culture, the effects of danazol on a human endometrial cancer cell line (IK-90 …

article 1986

Danazol binds to progesterone receptors and inhibits the growth of human endometrial cancer cells in vitro

·doi:10.1016/s0002-9378(86)80039-4

Based on our recent findings that danazol, an isoxazol derivative of ethinyltestosterone, has a profound growth-inhibitory effect on an established human endometrial adenocarcinoma cell line, the effects of danazol on cancer cells from huma…